RecruitingNCT05009537
Optical Genome Mapping in Hematological Malignancies
Sponsor
University Hospital, Brest
Enrollment
200 participants
Start Date
Sep 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
Eligibility
Inclusion Criteria3
- Minor/Major Patients
- Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
- No objection made or consent given
Exclusion Criteria2
- Patients under judicial protection (guardianship, curatorship, ...),
- Refusal to participate
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05009537
Related Trials
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
NCT018611061 location
Familial Investigations of Childhood Cancer Predisposition
NCT030502681 location
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
NCT074935381 location
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
NCT060478861 location
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
NCT041871051 location